Diamyd Medical AB
8 News & Press Releases found
Diamyd Medical AB news
An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM).
As communicated on 23 September 2021, treatment with Diamyd®
Sep. 30, 2022
Results of an analysis of a previous prevention trial with Diamyd® (GAD-alum) treatment, which indicate a positive and sustained immunomodulating effect after treatment with Diamyd® in healthy children at risk for type 1 diabetes, have been published in the scientific journal Journal of Immunology Research.
The analysis was carried out by researchers at Lund University and provides additional s
Sep. 30, 2022
The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. The trial includes 6 patients with Type 1 diabetes who earlier participated in the DIAGNODE-1 or DIAGNODE-2 trials and who carry the genetic HLA DR3-DQ2 haplotype. DIAGNODE-B (B for “booster”) assesses the safety, immunological response and clinical effect of an additional intralymph
Sep. 29, 2022
Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd® in individuals diagnosed with Latent Autoimmune Diabetes in Adults (LADA) were presented today at the European Association for the Study of Diabetes (EASD) conference in Stockholm, Sweden. The updated results provide further support to the previously reported topline
Sep. 20, 2022
An article presenting the 5-month interim results from the open-label trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal Frontiers in Endocrinology.
As communicated on December 7, 2021, immunological analyses after 5-months showed that the treatment with Diamyd® induced a clear GAD-specific immune r
Aug. 5, 2022
The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA, in which the diabetes vaccine Diamyd® was administered directly into the lymph node of 14 patients aged 30 to 70 years with the autoimmune form of diabetes called LADA (Latent Autoimmune Diabetes in Adults). Analyses also showed a positive immunological response to the treatment and the clinical course appears promising wi
Jul. 7, 2022
Diamyd Medical will be a full voting member of the Type 1 Diabetes Consortium (T1DC) led by the US non-profit organization the Critical Path Institute (C-Path). The T1DC brings together diverse stakeholders from industry, academia and patient organizations to develop solutions to accelerate drug development for Type 1 Diabetes, including biomarker endpoints and model-informed drug development tools in close collaboration with regulatory agencies to enable easier and faster regulatory ap
Jun. 30, 2022
The first patient has now received its first intralymphatic injection of Diamyd® in the precision medicine Phase III trial DIAGNODE-3. The trial will include approximately 330 patients aged 12 to 29 years newly diagnosed with Type 1 Diabetes who carry the genetically defined haplotype HLA DR3-DQ2.
“The fact that the first patient is now enrolled in DIAGNODE-3 is a major milestone for the therapeutic diabetes vaccin
May. 19, 2022